跳至主要内容
临床试验/NCT06438705
NCT06438705招募中不适用

Clinical Application of a Novel 99mTc Labeled Fibroblast Activating Protein (FAP) Targeted Molecular Probe in Early Diagnosis of Tumors

Nanjing First Hospital, Nanjing Medical University1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2024年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
20
试验地点
1
主要终点
Tumor uptake

研究概览

简要总结

At present, radiopharmaceuticals targeting FAP have been developed for the diagnosis and treatment of various tumors. Considering the problems of fast tumor tissue clearance and short retention time in small molecule FAP inhibitors based on quinoline rings, this project optimized their ligands and developed a new FAP targeted technetium labeled molecular imaging probe for SPECT/CT imaging research to evaluate its safety in clinical application and its effectiveness in tumor diagnosis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Voluntary subjects, patients or their legal representatives sign informed consent;
  • Volunteers are of any gender and aged between 18 and 75 years old, including the cut-off value;
  • Other imaging methods found tumor occupying;
  • Patients with pre-treatment tumors for whom surgery or biopsy may be performed to obtain final pathological results.
  • Kidney glomerular filtration rate(GFR)>50 ml/min, effective renal plasma flow(ERPF)>280 ml/min, platelet count (PLT) >75 000/μL, white blood cell (WBC) >3000/μL, alanine aminotransferase ALT, aspartate aminotransferase AST less than 3 times the normal value.

排除标准

  • People who have a history of allergy to similar drugs , allergic constitution or are currently suffering from allergic diseases;
  • Is conducting clinical research on other drugs, or has participated in clinical research on any drugs (excluding vitamins and minerals);
  • Have other clinical problems that are difficult to control (such as hepatitis C virus infection or active hepatitis B, or other serious chronic infections and serious mental, neurological, cardiovascular, respiratory and other diseases);
  • Obvious abnormal liver and kidney function, GFR less than 50 ml/min;
  • Tumor load is greater than 50%, or there is obvious spinal cord compression;
  • The expected survival period is less than half a year; Chemotherapy was performed within 6 months.
  • Have severe acute concomitant diseases or serious refractory mental disorders;
  • Pregnant and lactating women (where pregnancy is defined as a positive urine pregnancy study);
  • Patients whose physical condition is not suitable for radiological examination;
  • Other situations deemed inappropriate by the investigator to participate in the trial.

结局指标

主要结局

Tumor uptake

时间窗: 1 hour after administering the probe

Compare the lesion site with surrounding normal tissue to evaluate whether there is a significant increase in radioactive uptake. Select the lesion in the abnormal area of the image and draw a 3D area of interest (ROI) to obtain the average lesion volume count (T). Calculate the tumor target/non target value (T/NT) statistically

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Feng Wang

Chief physician

Nanjing First Hospital, Nanjing Medical University

研究点 (1)

Loading locations...

相似试验

99mTc Labeled FAP Targeted Molecular Probe in Early... | 临床试验